No Data
Smart Pharmaceuticals: 2024 Semi-Annual Report Summary
Smart Pharmaceuticals: 2024 Semi-Annual Report
Chempartner Pharmatech (300149.SZ): Net loss of 62.9065 million yuan in the first half of the year, with an expanded loss compared to the same period last year.
ChemPartner Pharmatech (300149.SZ) announced its semi-annual report for 2024 on August 29. The total operating income during the reporting period was 4.65 billion yuan, a decrease of 16.56% year-on-year; the net income attributable to the shareholders of the listed company was -62.9065 million yuan, with an expanded loss year-on-year; the net income attributable to the shareholders of the listed company after deducting non-recurring gains and losses was -64.0386 million yuan, with an expanded loss year-on-year; the basic earnings per share was -0.1263 yuan.
Chempartner Pharmatech (300149.SZ) announced its performance in the first half of the year, with a net loss of 62.9065 million yuan, an increase of 188.88%.
Chempartner Pharmatech (300149.SZ) released its semi-annual report for 2024, with revenue of 0.465 billion...
As of August 9, 2024, chempartner pharmatech (300149.SZ) had 32,558 shareholders.
Chempartner Pharmatech (300149.SZ) stated on the investor interaction platform that the number of shareholders as of August 9, 2024 was 32,558.
ChemPartner Pharmatech (300149.SZ): Currently, there is no research and development related to drugs for the mutated strain of monkeypox.
Chempartner Pharmatech (300149.SZ) stated on the investor interaction platform on August 16 that the company is currently not involved in the research and development of drugs related to the monkeypox variant strain.
Chempartner Pharmatech Co., Ltd.'s (SZSE:300149) Share Price Boosted 31% But Its Business Prospects Need A Lift TooNo Data
